NEUREXIS THERAPEUTICS, INC.
AURORA, CO · Founded 2020 · CIK 0001849201 · Biotech · Private
tatCN19o, a peptide inhibitor of CaMKII for neuroprotection after global cerebral ischemia
neurexistherapeutics.com →- Grants
- $3.3M
- 3 awards
- Sector median: 1
- Raised
- $605K
- 3 Form D · May 2022
- 53 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Preparing for IND-enabling safety studies for a potent and efficient neuroprotective drug. | $496,145 | |
| Private capital raised | Form D · SEC | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling studies for a potent and efficient neuroprotective drug | $938,239 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling studies for a potent and efficient neuroprotective drug | $1,833,347 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1179 | Pagari Life Science Corp. | — | $678K |
| 1180 | PRIMAL THERAPIES, INC. | — | $677K |
| 1181 | Grace Bio-Labs, Inc. | — | — |
| 1182 | NEUREXIS THERAPEUTICS, INC. | — | $605K |
| 1183 | IQuity Labs, Inc. | — | $600K |
| 1184 | Immunaeon Inc. | — | $250K |
| 1185 | Exxel Pharma, INC. | — | $600K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michael ArtingerDirector · Executive Officer
- K. BayerDirector
- Ulli BayerDirector
- Ulrich BayerDirector
- Robert GoforthDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.